证券代码：688426 证券简称：康为世纪 公告编号：2023-035 江苏康为世纪生物科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》和《上海证券交易所科创板股票上市规则》等相关规 定，江苏康为世纪生物科技股份有限公司（以下简称"公司"）就 2023年半年度募集资金 存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金的金额和资金到账时间 2022 年 9 月 1 日，经中国证券监督管理委员会《关于同意江苏康为世纪生物科技股 份有限公司首次公开发行股票注册的批复》（证监许可[2022]2003 号）核准，公司向社会 首次公开发行人民币普通股（A 股）股票 2,329.0278 万股，股票面值为人民币 1 元，发 行价格为每股人民币 48.98 元 ...

(本页以下无正文) 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易 所科创板股票上市规则》及《江苏康为世纪生物科技股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，我们作为江苏康为世纪生物科技股份有限公 司（以下简称"公司"）独立董事，本着对公司及全体股东负责的态度，基于独立、 客观、审慎的原则，现就公司第一届董事会第二十五次会议审议的相关事项发表 如下独立意见： 一、关于对《2023 年半年度募集资金存放与使用情况的专项报告》的独立 意见 公司编制的《2023 年半年度募集资金存放与使用情况的专项报告》符合《上 海证券交易所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》及《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求》等相关法律法规、规章及《江苏康为世纪生物科技股 份有限公司募集资金管理制度》的规定。不存在改变或变相改变募集资金用途的 情形，不存在损害公司及股东利益的情形，不会对募投项目的实施造成不利影响。 募集资金具体使用情况与公司已披露情况一致，不存在变相改变募集资金用途和 损害股东利益的情况，不存在违 ...

证券代码：688426 证券简称：康为世纪 公告编号：2023-037 江苏康为世纪生物科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2023 年 9 月 7 日（星期四）下午 13:00-15:00 ●会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com） ●会议召开方式：视频和线上文字互动 ●投资者可于 2023 年 9 月 5 日（星期二）中午 12:00 前登录上证路演中心网站 首页点击"提问预征集"栏目或通过公司邮箱 IRM@cwbio.cn 进行提问。公司将在本次业 绩说明会上对投资者普遍关注的、有代表性的问题逐条进行回答。 江苏康为世纪生物科技股份有限公司(下称"公司")已于 2023 年 8 月 30 日在上海 证券交易所网站（www.sse.com.cn）披露了《2023 年半年度报告》及其摘要，为了便 于广大投资者更全面、更深入地了解公司 2023 年半年度的经营成果、财务状况等信 息，公司参加了由上海 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥76,943,090.83, representing a decrease of 37.35% compared to the same period last year[3] - The net profit attributable to shareholders was ¥3,989,440.66, down 89.74% year-on-year[3] - The net cash flow from operating activities was -¥9,225,991.59, a decline of 127.19% compared to the previous year[3] - Total operating revenue for Q1 2023 was ¥76,943,090.83, a decrease of 37.4% compared to ¥122,814,896.09 in Q1 2022[17] - Net profit for Q1 2023 was ¥9,503,471.21, a decline of 75.5% from ¥38,880,499.79 in Q1 2022[18] - The company reported a comprehensive income total of ¥9,182,584.27 for Q1 2023, down from ¥38,865,774.28 in Q1 2022[18] - The company experienced a significant decrease in sales revenue, indicating potential challenges in market demand or competition[17] Research and Development - Research and development expenses totaled ¥19,039,632.01, which is an increase of 38.86% year-on-year[3] - The proportion of R&D expenses to operating revenue was 24.75%, an increase of 13.58 percentage points compared to the previous year[4] - Research and development expenses for Q1 2023 were ¥19,039,632.01, an increase of 38.8% from ¥13,711,047.94 in Q1 2022[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,940,172,963.71, a decrease of 0.51% from the end of the previous year[4] - As of March 31, 2023, the total current assets amounted to RMB 1,569,355,696.88, a decrease from RMB 1,626,664,083.19 as of December 31, 2022, reflecting a decline of approximately 3.5%[12] - The total liabilities decreased to RMB 1,569,355,696.88 from RMB 1,626,664,083.19, indicating a decline of approximately 3.5%[13] - Total liabilities as of Q1 2023 were ¥125,659,684.49, compared to ¥158,416,801.31 in the previous period[14] - The total non-current assets increased to RMB 370,817,266.83 from RMB 323,413,601.32, reflecting an increase of approximately 14.7%[13] Cash Flow - The cash and cash equivalents were reported at RMB 410,812,747.09, down from RMB 1,031,534,445.52, indicating a significant decrease of about 60.3%[12] - Cash inflow from operating activities in Q1 2023 was ¥66,528,597.93, down 48.0% from ¥128,091,616.53 in Q1 2022[19] - The net cash flow from operating activities was -$9,225,991.59, a significant decrease compared to $33,933,089.12 in the previous year, indicating a decline in operational performance[21] - The company reported a total cash outflow of $620,722,341.81 for the quarter, contrasting with a cash inflow of $134,161,295.71 in the same quarter last year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,413[8] - The largest shareholder, Beijing Kangwei Century Biotechnology Co., Ltd., holds 42,000,000 shares, accounting for 44.91% of the total shares[8] - Total equity attributable to shareholders was ¥1,791,684,776.75, an increase from ¥1,780,346,411.28 in the previous period[14] Operational Challenges - The company experienced a significant decline in main business income due to changes in market demand[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] Costs and Expenses - Total operating costs for Q1 2023 were ¥68,061,840.64, down 10.5% from ¥76,035,786.15 in Q1 2022[17] - The company paid $34,649,016.72 in employee compensation, up from $29,007,526.33, indicating increased labor costs[21] - Tax payments increased to $13,454,499.18 from $10,759,338.00, reflecting higher tax obligations[21] Investment Activities - Cash inflow from investment activities totaled $542,802,500.88, up from $234,976,184.10 year-over-year, reflecting increased investment recovery[21] - The cash outflow from investment activities was $1,158,990,407.49, compared to $132,533,414.96 in the previous year, resulting in a net cash flow from investment activities of -$616,187,906.61[21] Accounting Standards - The company is implementing new accounting standards starting in 2023, which may affect future financial reporting[22]

Financial Performance - In 2022, the company achieved a net profit attributable to shareholders of RMB 159,258,880.74, with a distributable profit of RMB 172,983,356.83 by the end of the year[5]. - The proposed profit distribution plan includes a cash dividend of RMB 5.20 per 10 shares, totaling RMB 48,631,945.96, which accounts for 30.54% of the net profit[5]. - The company has not yet achieved profitability since its listing[6]. - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2022, representing a year-over-year growth of 20%[14]. - The company's operating revenue for 2022 was CNY 521.6 million, representing a year-on-year increase of 54.11% compared to CNY 338.5 million in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 159.3 million, a 26.55% increase from CNY 125.8 million in 2021[24]. - The basic earnings per share for 2022 was CNY 2.16, a 20.00% increase from CNY 1.80 in 2021[25]. - The total assets at the end of 2022 reached CNY 1.95 billion, a 200.58% increase from CNY 648.8 million at the end of 2021[24]. - The net assets attributable to shareholders increased by 224.72% to CNY 1.78 billion at the end of 2022, compared to CNY 548.3 million at the end of 2021[24]. - The company reported a net cash flow from operating activities of CNY 107.4 million for 2022[24]. Research and Development - Research and development investments increased by 40%, focusing on next-generation sequencing technologies[15]. - Research and development expenses for 2022 totaled 74.02 million yuan, an increase of 91.83% compared to the previous year[38]. - The R&D team expanded to 185 members, a 40.15% increase from the previous year, with 71.35% holding master's degrees or higher[39]. - The company has developed 122 types of molecular detection raw enzymes, including Taq polymerase and high-fidelity PCR enzymes, with performance levels meeting or exceeding imported products[45]. - The company has established a comprehensive fluorescence quantitative molecular platform and a second-generation sequencing reagent R&D system for its nucleic acid detection kits[198]. Product Development and Innovation - The company plans to introduce a new point-of-care testing (POCT) product line in Q2 2023, aiming for a 15% contribution to total revenue[15]. - The company has launched several molecular diagnostic kits, including the first Class III registration certificate for Helicobacter pylori nucleic acid detection based on fecal samples, filling a gap in the industry[52]. - The company has developed a non-invasive prenatal trace gene testing kit, achieving a product launch with a market demand of 450 million[116]. - The company is focusing on the development of specific detection reagents and dedicated instruments to improve diagnostic effectiveness[83]. - The company has developed a series of alternative reagents for nucleic acid mass spectrometry, which are more cost-effective than imported products and reduce operational steps and detection time[97]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[16]. - The company is actively pursuing market expansion through the introduction of new diagnostic kits, such as the Monkeypox Virus Nucleic Acid Detection Kit, registered in June 2022[106]. - The company is collaborating with international giants and research institutions to leverage resources and expand its global market presence in molecular detection[83]. - The company is strategically positioned for future growth, leveraging its intellectual property and expanding its market presence both domestically and internationally[99]. Risk Management - The company has disclosed potential risk factors that may adversely affect its operations in the management discussion section[4]. - The company faces risks related to the slow progress and high costs of new product development, which may lead to potential failures in obtaining necessary registrations[129]. - The company is at risk of losing core technical personnel due to intense competition for talent in the molecular detection field[129]. - The company’s core technology and proprietary techniques are at risk of leakage if not effectively managed, which could adversely affect operations[129]. Compliance and Quality Assurance - The audit report issued by the accounting firm was a standard unqualified opinion[6]. - The company has ensured the accuracy and completeness of the annual report, with all board members present at the meeting[6]. - The company follows ISO9001:2015 and ISO13485:2016 quality management systems in its R&D processes, ensuring compliance and quality assurance[57]. Sales and Distribution - The company utilizes a "direct sales primarily, with distributors as a supplement" sales model, ensuring high cash return rates from direct sales to research institutions and medical testing labs[61]. - The company has established a sales network with five domestic sales regions and one international sales region, including marketing offices in ten cities such as Beijing, Shanghai, and Guangzhou[61]. - The company achieved overseas sales revenue of 33.45 million yuan, accounting for 6.41% of total sales during the reporting period[130]. Financial Position and Assets - Cash and cash equivalents at the end of the period reached ¥1,031,534,445.52, accounting for 52.90% of total assets, a significant increase of 707.03% compared to the previous period[163]. - The total procurement amount from the top five suppliers was 34.57 million, representing 17.62% of the annual total procurement, with no purchases from related parties[157]. - The company reported a significant increase in accounts payable to ¥44,070,076.95, which is 2.26% of total liabilities, reflecting a 148.21% increase driven by larger procurement volumes[165].

证券代码：688426 证券简称：康为世纪 公告编号：2023-011 江苏康为世纪生物科技股份有限公司 关于参加 2022 年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2023 年 4 月 26 日（星期三）下午 15:00-16:00 ●会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com） ●会议召开方式：视频与网络文字互动 ●投资者可于 2023 年 4 月 26 日（星期三）中午 12:00 前登录上证路演中心网站 首页点击"提问预征集"栏目或通过公司邮箱 kangweishiji@cwbio.cn 进行提问。公司将 在本次业绩说明会上对投资者普遍关注的、有代表性的问题逐条进行回答。 江苏康为世纪生物科技股份有限公司(下称"公司")已于 2023 年 2 月 28 日在上海 证券交易所网站（www.sse.com.cn）披露了《2022 年度业绩快报公告》（公告编号： 2023-009）, ...